New Clarification Regarding Post Transplant Testing

In a recent announcement, the Centers for Medicare & Medicaid Services (CMS) underscored its commitment to ensuring continued access to essential blood tests for Medicare beneficiaries with transplanted hearts, lungs, or kidneys.

These blood tests, vital for monitoring organ rejection, remain available to patients who meet specific coverage criteria and have been prescribed by their physicians in medically appropriate circumstances. The clarification comes after CMS, through its local contractors—known as Medicare Administrative Contractors (MACs)—updated billing instructions in March 2023 to combat issues of improper billing and overutilization.

The action by CMS reaffirms the agency’s dedication to patient care and the precise billing practices required in the healthcare system. These billing instructions are crucial for healthcare providers, outlining the correct procedures for billing Medicare for covered services. The recent updates made by the MACs aim to rectify any confusion that might have arisen from earlier billing articles, ensuring that both physicians and patients understand that these critical tests are still accessible when deemed medically necessary.

Background information provided by CMS highlights the role of the MACs in developing local coverage determinations (LCDs). These LCDs guide the coverage of specific services in their jurisdictions, provided they do not conflict with national coverage policies. One innovative initiative, the Molecular Diagnostic Services Program (MolDX), developed by Palmetto GBA, a MAC, exemplifies efforts to establish coverage and payment for molecular diagnostic tests. This program and similar efforts by other MACs emphasize the technical and specialized nature of evaluating molecular diagnostics and technology, incorporating insights from laboratory medicine and genomics.

The necessity for the revised billing and coding article, issued on March 31, 2023, emerged from observations of improper billing practices and the overutilization of certain tests, which did not align with the coverage guidelines outlined in the LCD. The MACs sought to distinguish between surveillance tests (conducted as part of a protocol) and for-cause tests (initiated due to symptoms of rejection), with the goal of ensuring that laboratory billing practices adhered to Medicare requirements. The feedback from various stakeholders prompted the MACs to revise the article, reintroducing a table that lists the solid organ allograft rejection tests covered under the indications specified in the LCD.

Further, CMS and the MACs have demonstrated a willingness to engage with the medical community and the public on these critical issues. For instance, on Aug. 10, 2023, the MACs released a proposed LCD inviting comments and evidence from the public regarding proposed changes aimed at clarifying existing coverage policies. The period for public comment, which ended on Sept. 23, 2023, reflects the open approach by CMS to policy development, ensuring that decisions are informed by a broad range of perspectives and evidence.

As the MACs review public comments and clinical evidence submitted in response to the proposed LCD, the healthcare community awaits further guidance.

Recent actions by CMS, including the issuance of the revised billing article, signal a clear expectation that physicians will continue prescribing these essential post-transplant tests for eligible patients. Looking ahead, the finalization of the proposed LCD will lead to the issuance of a final LCD that explains the rationale behind coverage decisions, accompanied by a new billing and coding article to further educate healthcare providers about the proper coding and billing procedures for these tests.

In summary, the efforts by CMS to clarify billing instructions for blood tests used to monitor for organ transplantation rejection underscore its commitment to ensuring that Medicare beneficiaries continue to have access to necessary medical care. By addressing challenges related to improper billing and overutilization, and by fostering open dialogue with the healthcare community and the public, CMS is taking significant steps to support patient care and the sustainability of the Medicare program.